Clinical Trial Update: A Study of Neoadjuvant Paclitaxel in Combination With Bavituximab in Early- Stage Triple- Negative Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating neoadjuvant paclitaxel in combination with bavituximab for early-stage triple-negative breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Bavituximab (bavituximab)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Peregrine Pharmaceuticals | Conditions: Breast Cancer, Triple Negative Breast Neoplasms | Phase 2 | Status: WITHDRAWN